Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
David J. Heal(IDEXX Laboratories (France)), Sharon L. Smith(IDEXX Laboratories (France)), Jane Gosden(RenaSci (United Kingdom))
Cited by 87
Related Papers
Amphetamine, past and present – a pharmacological and clinical perspective
|Journal of Psychopharmacology|2013|614
Experimental Approaches to Anxiety and Depression
|Behavioural Pharmacology|1993|363
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology
|Journal of Psychopharmacology|2014|284
The pharmacology of the behavioral and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)
|Psychopharmacology|1987|198
The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
|Neuropharmacology|2009|197